Danish pharmaceutical firm Novo Nordisk has elected Brian Daniels as a new member of its board of directors.
He brings over 20 years of pharmaceutical management expertise to the board, having served as director of immunology at MSD and vice president of immunology then senior vice president of global development and medical affairs at Bristol-Myers Squibb.
Currently, Daniels serves as a senior advisor to the Boston Consulting Group and a venture partner for 5AM Venture Management, both of which are based in the US.
In a statement, Novo Nordisk’s board of directors said it had recommended Daniels because of “his extensive experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutic areas”.
Novo Nordisk also announced the re-election of Goran Ando, Jeppe Christiansen, Bruno Angelici, Sylvie Gregoire, Liz Hewitt and Mary Szela to the board of directors.
Source: PMLive
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
